Nymox Announces Symposium for Company's BPH Drug at American Urological Association Meeting in September
07 août 2017 10h00 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an important large symposium and panel assessment of the...
Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
31 mai 2017 10h00 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce statistically significant clinical trial results showing that the...
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
10 mai 2017 11h15 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number...
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT
08 mai 2017 11h00 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Following Nymox's announcement of the Company's filing for marketing approval of Fexapotide...
NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
03 mai 2017 09h30 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company has filed to seek approval for marketing...
Nymox Provides Update on Fexapotide Development
29 mars 2017 10h45 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) provided an update today on the Company's development activities for Fexapotide...
Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
29 nov. 2016 09h45 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that new Phase 3 prospective randomized clinical trial results have...
Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment
11 oct. 2016 10h00 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term repeated...
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
29 août 2016 10h30 HE
|
Nymox Pharmaceutical Corporation
1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation...
Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
24 août 2016 12h18 HE
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the...